FDA panel to review PPIs in GERD for the very young
This article was originally published in Scrip
Executive Summary
The US FDA's gastro-intestinal drugs advisory committee will meet on 5 November to discuss the results from clinical trials of proton pump inhibitors in gastro-esophageal reflux disease (GERD) in patients less than one year of age.